Today: 3 March 2026
Subscribe
Browse Category

Stock Market 17 October 2025

Shell’s $2 Billion Nigeria Gas Gamble Ignites LNG Boom Amid $8 B Investment Surge

Shell’s Bold $2 Billion Bet and Oil Price Twist: What’s Next for Shell Stock?

Shell plc shares closed at 2,672 pence in London on October 17, up 3.6% for the week after volatile trading. The company approved a $2 billion offshore gas project in Nigeria and raised its Q3 outlook, with analysts forecasting strong earnings on October 30. Brent crude hovered near $62 a barrel, pressuring valuations, but Shell continued buybacks. Twelve analysts rate the stock “Buy,” with a target near 3,100 GBp.
17 October 2025
··
Lloyds Share Price: Can the FTSE‑100 Bank’s Value Keep Surging or Is a Crash Coming?

Lloyds Stock Nears Decade High as Bank Shrugs Off £2bn Scandal Hit

Lloyds Banking Group shares rebounded from an early 3% drop to trade near 85 pence on Friday, close to a 10-year high. The bank added £800 million to provisions for a UK car loan mis-selling scandal, bringing total charges to £1.95 billion. Lloyds’ stock is up about 50% year-on-year, defying a broader bank selloff. First-half net interest income rose 5% to £6.7 billion.
17 October 2025
·
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
Rolls-Royce Soars to Record High: What’s Fueling the Unstoppable Rally?

Rolls-Royce Stock Skyrockets to Record High – Will It Climb Higher or Run Out of Fuel?

Rolls-Royce shares have doubled in 2025, recently hitting a record near 1,196p before easing to £11.10 as investors took profits. First-half profit surged 50% to £1.7 billion, prompting a raised outlook and new initiatives, including a £2.5 billion UK reactor project. The company resumed dividends and launched a £1 billion buyback. Analysts remain split on valuation as the stock trades at 40× forward earnings.
17 October 2025
·
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
Akanda Corp (AKAN) Soars on Telecom Expansion – What It Means for Investors

Akanda Corp (AKAN) Soars on Telecom Expansion – What It Means for Investors

Akanda Corp. shares surged 36% in after-hours trading on Oct. 16 after announcing plans to build or acquire up to 20 cellular towers in Mexico by end-2025. The stock jumped from $2.23 to $2.85 overnight, driven by the company's tiny float of under 730,000 shares. Akanda pivoted to telecom infrastructure after merging with First Towers & Fiber in August 2025. Market cap remains below $2 million.
17 October 2025
·
Jefferies Stock Plunge Deepens Amid Bankruptcy Fallout – Will a Rebound Follow?

Jefferies Stock Plunge Deepens Amid Bankruptcy Fallout – Will a Rebound Follow?

Jefferies Financial Group shares dropped over 10% on Oct. 16 to $48.80, extending a month-to-date loss of about 25% after revealing $715 million in exposure to bankrupt First Brands Group. Multiple law firms launched probes into possible investor misstatements. Executives insist losses are manageable and called the selloff “overdone.” The decline came as other U.S. banks reported credit issues, fueling sector-wide concerns.
17 October 2025
··
Safe & Green (SGBX) Roars Back: Nasdaq Lifeline and AI Pivot Fuel Wild Stock Ride

Safe & Green (SGBX) Roars Back: Nasdaq Lifeline and AI Pivot Fuel Wild Stock Ride

Safe & Green Holdings regained Nasdaq compliance on Oct. 3, 2025, after a 1-for-64 reverse split and restructuring a financing deal. Shares surged 86.7% to $6.03 before retreating to $3. Executives took Q3 pay in stock, and the company is moving operations to a new Texas facility. FY2024 revenue fell to $4.98 million, with a net loss of $16.98 million; market cap stands at $1.5 million.
17 October 2025
···
$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears

$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears

Zions Bancorp reported a $50 million loan loss tied to alleged fraud, sending its shares down 13% on October 16. Western Alliance stock fell 11% after filing a related fraud lawsuit. The news erased over $100 billion from U.S. bank stocks, dragging the KBW Regional Banking Index down 5–6% and major indexes lower. European bank shares also tumbled, with Germany’s DAX dropping below 24,000.
17 October 2025
····
Deutsche Bank Stock Plunges Again as Global Credit Jitters Flare – What Experts Predict Next

Deutsche Bank Stock Plunges Again as Global Credit Jitters Flare – What Experts Predict Next

Deutsche Bank shares fell about 6% to €28.60 on Friday, among the worst DAX performers as the index dropped 2% amid global market turmoil. The sell-off followed surprise loan losses and alleged fraud at two U.S. regional banks, sparking fears of wider credit stress. European bank stocks slid roughly 3%, with Barclays also down over 5%. Gold surged to a record above $4,378/oz as investors sought safe havens.
17 October 2025
·
Nasdaq Warning and EV Ambitions: Carbon Revolution (CREV) Races to Reinvent Itself

Nasdaq Warning and EV Ambitions: Carbon Revolution (CREV) Races to Reinvent Itself

Carbon Revolution faces possible Nasdaq delisting after failing equity and filing requirements, with deadlines set for late 2025. CREV shares traded at $3.73 on Oct. 17, 2025, down over 70% from their 52-week high, valuing the company under $7 million. Fiscal 2024 revenue hit a record $47.3 million, but net loss reached $146.4 million. The company warned it needs more funding within a quarter to remain solvent.
17 October 2025
··
Credit ‘Cockroach’ Jitters Shake Markets: Stocks Slide Globally as Gold Hits Record High

Credit ‘Cockroach’ Jitters Shake Markets: Stocks Slide Globally as Gold Hits Record High

Global stocks tumbled Thursday as fresh U.S. regional bank troubles triggered a worldwide selloff. The Dow fell 410 points, while Zions Bancorp and Western Alliance shares dropped 10% after disclosing bad loans and alleged fraud. Gold hit a record $4,378/oz as investors rushed to safe havens. Europe’s bank index slid 2.7%, and major Asian markets closed sharply lower.
17 October 2025
·······
Fraud Scandals Spark Market Selloff as ‘Cockroach’ Credit Fears Mount

Fraud Scandals Spark Market Selloff as ‘Cockroach’ Credit Fears Mount

Over $100 billion in U.S. bank market value was erased Thursday as the Dow fell nearly 400 points and the KBW Regional Banking Index dropped 6%. Zions Bancorp and Western Alliance plunged after disclosing fraud-related loan losses, sparking broad financial sector selloffs. Gold hit a record above $4,370/oz and Treasury yields slid as investors fled to safe havens. Wall Street leaders warned of wider credit risks.
17 October 2025
···
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics shares surged nearly 100% in after-hours trading Oct. 16 after the FDA granted Fast Track status to its AlloNK cell therapy for refractory rheumatoid arthritis. The stock jumped from a $2.77 close to as high as $6.33. Over 20 patients have received AlloNK in trials, with key safety and mechanistic data expected by mid-November. Artiva plans to begin a pivotal Phase 3 trial in 2026, pending results.
17 October 2025
·
Truist’s Q3 Earnings Beat and 5% Dividend Yield Trigger Rally as Analysts Grow Bullish

Truist’s Q3 Earnings Beat and 5% Dividend Yield Trigger Rally as Analysts Grow Bullish

Truist Financial reported Q3 earnings of $1.04 per share, beating estimates, with net income rising to $1.35 billion on $5.24 billion revenue. Shares jumped 4% after results but remain down 5.3% year-to-date. Fee income surged 11% sequentially, offsetting flat net interest income. The bank maintained its $0.52 dividend and repurchased $500 million in stock.
17 October 2025
···
Reliance Q2 Results Boost Investor Hopes – Double-Digit Growth, Jio IPO Buzz & Stock Breakout?

Reliance Q2 Results Boost Investor Hopes – Double-Digit Growth, Jio IPO Buzz & Stock Breakout?

Reliance Industries is expected to report Q2 FY26 net profit of ₹18,000–21,000 crore, up about 10% year-on-year, with revenue rising to ₹2.52–2.57 lakh crore. The gains are driven by strong oil-to-chemicals margins and growth in Jio and retail. The stock has rebounded 4% in October after a post-Q1 drop. Investors await updates on a potential Jio IPO and progress in new energy and AI initiatives.
17 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly shares hit a record $832 intraday on Oct. 1, fueled by demand for its obesity drugs and Alzheimer’s advances, before slipping 4% after Donald Trump pledged to cut weight-loss drug prices. Lilly’s Mounjaro and ZepBound now hold 57% of U.S. GLP-1 prescriptions, outpacing Novo Nordisk. First-half 2025 revenue jumped about 40% year-on-year. Most analysts remain bullish, despite valuation and policy concerns.
17 October 2025
··
1 … 1,261 1,262 1,263 1,264 1,265 … 1,327
Go toTop